The Safety and Efficacy of BDL(Bedaquiline Plus Delamanid Plus Linezolid) Regimen in Subjects With Pulmonary Infection of Multi-drug Resistant Tuberculosis (MDR-TB) or Rifampicin-Resistant Tuberculosis (RR-TB)
Latest Information Update: 24 Feb 2025
At a glance
- Drugs Bedaquiline (Primary) ; Delamanid (Primary) ; Linezolid (Primary)
- Indications Tuberculosis
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 15 Jul 2024 New trial record